Epithelial–Mesenchymal Transition Induced by TNF-α Requires NF-κB–Mediated Transcriptional Upregulation of Twist1
Proinflammatory cytokines produced in the tumor microenvironment facilitate tumor development and metastatic progression. In particular, TNF-α promotes cancer invasion and angiogenesis associated with epithelial–mesenchymal transition (EMT); however, the mechanisms underlying its induction of EMT in...
Saved in:
Published in | Cancer research (Chicago, Ill.) Vol. 72; no. 5; pp. 1290 - 1300 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Philadelphia, PA
American Association for Cancer Research
01.03.2012
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Proinflammatory cytokines produced in the tumor microenvironment facilitate tumor development and metastatic progression. In particular, TNF-α promotes cancer invasion and angiogenesis associated with epithelial–mesenchymal transition (EMT); however, the mechanisms underlying its induction of EMT in cancer cells remain unclear. Here we show that EMT and cancer stemness properties induced by chronic treatment with TNF-α are mediated by the upregulation of the transcriptional repressor Twist1. Exposure to TNF-α rapidly induced Twist1 mRNA and protein expression in normal breast epithelial and breast cancer cells. Both IKK-β and NF-κB p65 were required for TNF-α–induced expression of Twist1, suggesting the involvement of canonical NF-κB signaling. In support of this likelihood, we defined a functional NF-κB–binding site in the Twist1 promoter, and overexpression of p65 was sufficient to induce transcriptional upregulation of Twist1 along with EMT in mammary epithelial cells. Conversely, suppressing Twist1 expression abrogated p65-induced cell migration, invasion, EMT, and stemness properties, establishing that Twist1 is required for NF-κB to induce these aggressive phenotypes in breast cancer cells. Taken together, our results establish a signaling axis through which the tumor microenvironment elicits Twist1 expression to promote cancer metastasis. We suggest that targeting NF-κB–mediated Twist1 upregulation may offer an effective a therapeutic strategy for breast cancer treatment. Cancer Res; 72(5); 1290–300. ©2012 AACR. |
---|---|
AbstractList | Proinflammatory cytokines produced in the tumor microenvironment facilitate tumor development and metastatic progression. In particular, TNF- alpha promotes cancer invasion and angiogenesis associated with epithelial-mesenchymal transition (EMT); however, the mechanisms underlying its induction of EMT in cancer cells remain unclear. Here we show that EMT and cancer stemness properties induced by chronic treatment with TNF- alpha are mediated by the upregulation of the transcriptional repressor Twist1. Exposure to TNF- alpha rapidly induced Twist1 mRNA and protein expression in normal breast epithelial and breast cancer cells. Both IKK- beta and NF- Kappa B p65 were required for TNF- alpha -induced expression of Twist1, suggesting the involvement of canonical NF- Kappa B signaling. In support of this likelihood, we defined a functional NF- Kappa B-binding site in the Twist1 promoter, and overexpression of p65 was sufficient to induce transcriptional upregulation of Twist1 along with EMT in mammary epithelial cells. Conversely, suppressing Twist1 expression abrogated p65-induced cell migration, invasion, EMT, and stemness properties, establishing that Twist1 is required for NF- Kappa B to induce these aggressive phenotypes in breast cancer cells. Taken together, our results establish a signaling axis through which the tumor microenvironment elicits Twist1 expression to promote cancer metastasis. We suggest that targeting NF- Kappa B-mediated Twist1 upregulation may offer an effective a therapeutic strategy for breast cancer treatment. Cancer Res; 72(5); 1290-300. [copy]2012 AACR. Proinflammatory cytokines produced in the tumor microenvironment facilitate tumor development and metastatic progression. In particular, TNF-α promotes cancer invasion and angiogenesis associated with epithelial-mesenchymal transition (EMT); however, the mechanisms underlying its induction of EMT in cancer cells remain unclear. Here we show that EMT and cancer stemness properties induced by chronic treatment with TNF-α are mediated by the upregulation of the transcriptional repressor Twist1. Exposure to TNF-α rapidly induced Twist1 mRNA and protein expression in normal breast epithelial and breast cancer cells. Both IKK-β and NF-κB p65 were required for TNF-α-induced expression of Twist1, suggesting the involvement of canonical NF-κB signaling. In support of this likelihood, we defined a functional NF-κB-binding site in the Twist1 promoter, and overexpression of p65 was sufficient to induce transcriptional upregulation of Twist1 along with EMT in mammary epithelial cells. Conversely, suppressing Twist1 expression abrogated p65-induced cell migration, invasion, EMT, and stemness properties, establishing that Twist1 is required for NF-κB to induce these aggressive phenotypes in breast cancer cells. Taken together, our results establish a signaling axis through which the tumor microenvironment elicits Twist1 expression to promote cancer metastasis. We suggest that targeting NF-κB-mediated Twist1 upregulation may offer an effective a therapeutic strategy for breast cancer treatment. Proinflammatory cytokines produced in the tumor microenvironment facilitate tumor development and metastatic progression. In particular, TNF-α promotes cancer invasion and angiogenesis associated with epithelial-mesenchymal transition (EMT); however, the mechanisms underlying its induction of EMT in cancer cells remain unclear. Here we show that EMT and cancer stemness properties induced by chronic treatment with TNF-α are mediated by the upregulation of the transcriptional repressor Twist1. Exposure to TNF-α rapidly induced Twist1 mRNA and protein expression in normal breast epithelial and breast cancer cells. Both IKK-β and NF-κB p65 were required for TNF-α-induced expression of Twist1, suggesting the involvement of canonical NF-κB signaling. In support of this likelihood, we defined a functional NF-κB-binding site in the Twist1 promoter, and overexpression of p65 was sufficient to induce transcriptional upregulation of Twist1 along with EMT in mammary epithelial cells. Conversely, suppressing Twist1 expression abrogated p65-induced cell migration, invasion, EMT, and stemness properties, establishing that Twist1 is required for NF-κB to induce these aggressive phenotypes in breast cancer cells. Taken together, our results establish a signaling axis through which the tumor microenvironment elicits Twist1 expression to promote cancer metastasis. We suggest that targeting NF-κB-mediated Twist1 upregulation may offer an effective a therapeutic strategy for breast cancer treatment.Proinflammatory cytokines produced in the tumor microenvironment facilitate tumor development and metastatic progression. In particular, TNF-α promotes cancer invasion and angiogenesis associated with epithelial-mesenchymal transition (EMT); however, the mechanisms underlying its induction of EMT in cancer cells remain unclear. Here we show that EMT and cancer stemness properties induced by chronic treatment with TNF-α are mediated by the upregulation of the transcriptional repressor Twist1. Exposure to TNF-α rapidly induced Twist1 mRNA and protein expression in normal breast epithelial and breast cancer cells. Both IKK-β and NF-κB p65 were required for TNF-α-induced expression of Twist1, suggesting the involvement of canonical NF-κB signaling. In support of this likelihood, we defined a functional NF-κB-binding site in the Twist1 promoter, and overexpression of p65 was sufficient to induce transcriptional upregulation of Twist1 along with EMT in mammary epithelial cells. Conversely, suppressing Twist1 expression abrogated p65-induced cell migration, invasion, EMT, and stemness properties, establishing that Twist1 is required for NF-κB to induce these aggressive phenotypes in breast cancer cells. Taken together, our results establish a signaling axis through which the tumor microenvironment elicits Twist1 expression to promote cancer metastasis. We suggest that targeting NF-κB-mediated Twist1 upregulation may offer an effective a therapeutic strategy for breast cancer treatment. Proinflammatory cytokines produced in the tumor microenvironment facilitate tumor development and metastatic progression. In particular, TNF-α promotes cancer invasion and angiogenesis associated with epithelial–mesenchymal transition (EMT); however, the mechanisms underlying its induction of EMT in cancer cells remain unclear. Here we show that EMT and cancer stemness properties induced by chronic treatment with TNF-α are mediated by the upregulation of the transcriptional repressor Twist1. Exposure to TNF-α rapidly induced Twist1 mRNA and protein expression in normal breast epithelial and breast cancer cells. Both IKK-β and NF-κB p65 were required for TNF-α–induced expression of Twist1, suggesting the involvement of canonical NF-κB signaling. In support of this likelihood, we defined a functional NF-κB–binding site in the Twist1 promoter, and overexpression of p65 was sufficient to induce transcriptional upregulation of Twist1 along with EMT in mammary epithelial cells. Conversely, suppressing Twist1 expression abrogated p65-induced cell migration, invasion, EMT, and stemness properties, establishing that Twist1 is required for NF-κB to induce these aggressive phenotypes in breast cancer cells. Taken together, our results establish a signaling axis through which the tumor microenvironment elicits Twist1 expression to promote cancer metastasis. We suggest that targeting NF-κB–mediated Twist1 upregulation may offer an effective a therapeutic strategy for breast cancer treatment. Cancer Res; 72(5); 1290–300. ©2012 AACR. |
Author | Lim, Seung-Oe Wu, Yun Yamaguchi, Hirohito Wu, Ting-Jung Ding, Qingqing Hung, Mien-Chie Yang, Neng-Kai Huo, Longfei Lai, Yun-Ju Lin, Been-Ren Hortobagyi, Gabriel N. Wang, Yan Hsu, Jennifer L. Li, Chia-Wei Xia, Weiya LaBaff, Adam M. Yang, Muh-Hwa Chao, Chi-Hong |
Author_xml | – sequence: 1 givenname: Chia-Wei surname: Li fullname: Li, Chia-Wei – sequence: 2 givenname: Weiya surname: Xia fullname: Xia, Weiya – sequence: 3 givenname: Longfei surname: Huo fullname: Huo, Longfei – sequence: 4 givenname: Seung-Oe surname: Lim fullname: Lim, Seung-Oe – sequence: 5 givenname: Yun surname: Wu fullname: Wu, Yun – sequence: 6 givenname: Jennifer L. surname: Hsu fullname: Hsu, Jennifer L. – sequence: 7 givenname: Chi-Hong surname: Chao fullname: Chao, Chi-Hong – sequence: 8 givenname: Hirohito surname: Yamaguchi fullname: Yamaguchi, Hirohito – sequence: 9 givenname: Neng-Kai surname: Yang fullname: Yang, Neng-Kai – sequence: 10 givenname: Qingqing surname: Ding fullname: Ding, Qingqing – sequence: 11 givenname: Yan surname: Wang fullname: Wang, Yan – sequence: 12 givenname: Yun-Ju surname: Lai fullname: Lai, Yun-Ju – sequence: 13 givenname: Adam M. surname: LaBaff fullname: LaBaff, Adam M. – sequence: 14 givenname: Ting-Jung surname: Wu fullname: Wu, Ting-Jung – sequence: 15 givenname: Been-Ren surname: Lin fullname: Lin, Been-Ren – sequence: 16 givenname: Muh-Hwa surname: Yang fullname: Yang, Muh-Hwa – sequence: 17 givenname: Gabriel N. surname: Hortobagyi fullname: Hortobagyi, Gabriel N. – sequence: 18 givenname: Mien-Chie surname: Hung fullname: Hung, Mien-Chie |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25863056$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/22253230$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkU1O3DAYhq2Kqgw_RyjKpoJNwL-Jo66GEVAkSiU0rC3H-QKuPEmwE6HZ9Q49CVsOwSE4SZ1hoBKLdmV91vO8i_fdQhtN2wBCnwk-JETII4yxTAXP6eFsepkSkjJC2Qc0IYLJNOdcbKDJG7OJtkL4GU9BsPiENimlglGGJ-j-pLP9LTir3fOv398hQGNulwvtkrnXTbC9bZvkvKkGA1VSLpP55Wn69JBcwd1gPYRkPB-PV2pldR-hlWe87UY15lx3Hm4Gp1dJbZ3M723oyQ76WGsXYHf9bqPr05P57Ft68ePsfDa9SA0nsk8l5VlhRFXlHEOBaUYFlKC1yUFUmRSFLCnULKPAckmzupQ5EI15IWqm86Ji22j_Jbfz7d0AoVcLGww4pxtoh6CKgpGIMx7Jg3-SJJYpGeN8RPfW6FAuoFKdtwvtl-q11gh8WQM6GO3qWImx4S8nZMawyCInXjjj2xA81G8IwWqcWY0TqnFCFWeOX2qcOXpf33nG9quGe6-t-4_9Bzqxr9I |
CODEN | CNREA8 |
CitedBy_id | crossref_primary_10_1038_s41598_017_00916_z crossref_primary_10_1371_journal_pone_0137229 crossref_primary_10_1158_0008_5472_CAN_18_2502 crossref_primary_10_1158_0008_5472_CAN_18_0562 crossref_primary_10_1371_journal_pone_0247550 crossref_primary_10_3892_ijmm_2017_3320 crossref_primary_10_1016_j_prp_2025_155873 crossref_primary_10_1016_j_cbi_2013_01_005 crossref_primary_10_3390_ijms24010759 crossref_primary_10_1016_j_biopha_2023_114822 crossref_primary_10_1080_2162402X_2024_2393442 crossref_primary_10_1158_1078_0432_CCR_17_1963 crossref_primary_10_1007_s13402_021_00609_w crossref_primary_10_1038_s41598_024_52204_2 crossref_primary_10_1186_1472_6882_14_197 crossref_primary_10_1186_s40170_016_0160_x crossref_primary_10_1038_s41388_018_0618_0 crossref_primary_10_1038_s41419_020_2415_2 crossref_primary_10_1038_srep12520 crossref_primary_10_3390_ijms22095019 crossref_primary_10_1016_j_bcp_2018_10_031 crossref_primary_10_1016_j_cyto_2018_03_020 crossref_primary_10_1038_onc_2016_394 crossref_primary_10_1002_mco2_347 crossref_primary_10_1016_j_canlet_2016_02_015 crossref_primary_10_1038_s41467_017_01781_0 crossref_primary_10_1007_s12032_017_0980_8 crossref_primary_10_1080_2162402X_2017_1388485 crossref_primary_10_3390_cells5020016 crossref_primary_10_1007_s13402_015_0236_6 crossref_primary_10_1002_mc_23066 crossref_primary_10_1016_j_jare_2024_07_030 crossref_primary_10_1016_j_fertnstert_2013_10_032 crossref_primary_10_1038_s42003_020_01200_z crossref_primary_10_1109_ACCESS_2023_3283291 crossref_primary_10_1016_j_bbrc_2018_04_101 crossref_primary_10_1111_jcmm_18064 crossref_primary_10_1038_s41598_019_44835_7 crossref_primary_10_1016_j_bbamcr_2019_118537 crossref_primary_10_18632_oncotarget_4484 crossref_primary_10_3349_ymj_2020_61_9_816 crossref_primary_10_3389_fimmu_2021_656908 crossref_primary_10_3892_or_2016_5319 crossref_primary_10_1016_j_bbrep_2015_11_007 crossref_primary_10_1016_j_rvsc_2014_02_005 crossref_primary_10_1017_erm_2017_6 crossref_primary_10_1177_0300060515581671 crossref_primary_10_1021_acs_analchem_4c05947 crossref_primary_10_3892_or_2016_5317 crossref_primary_10_1016_j_rpor_2020_04_004 crossref_primary_10_3892_ijmm_2019_4319 crossref_primary_10_1186_1939_4551_7_13 crossref_primary_10_1111_imm_13486 crossref_primary_10_1038_s41598_017_08537_2 crossref_primary_10_18632_oncotarget_7521 crossref_primary_10_1007_s13277_014_2899_4 crossref_primary_10_3389_fcell_2021_662754 crossref_primary_10_1038_bjc_2014_141 crossref_primary_10_1016_j_bbrc_2013_06_115 crossref_primary_10_1038_s41419_018_1225_2 crossref_primary_10_1111_his_12309 crossref_primary_10_1111_biom_12893 crossref_primary_10_1089_scd_2016_0308 crossref_primary_10_1016_j_phymed_2015_03_007 crossref_primary_10_1007_s10517_016_3314_5 crossref_primary_10_1371_journal_pone_0070334 crossref_primary_10_1007_s10911_023_09553_x crossref_primary_10_1158_0008_5472_CAN_15_1941 crossref_primary_10_1007_s12020_015_0714_7 crossref_primary_10_3390_cancers15051495 crossref_primary_10_1080_19336918_2019_1568139 crossref_primary_10_1016_j_cyto_2020_155066 crossref_primary_10_1371_journal_pone_0066070 crossref_primary_10_1080_19336950_2023_2208928 crossref_primary_10_1016_j_jtauto_2021_100096 crossref_primary_10_3892_or_2016_4927 crossref_primary_10_1016_j_pvr_2016_11_003 crossref_primary_10_1002_jcb_24896 crossref_primary_10_1186_s13046_019_1196_x crossref_primary_10_18632_oncotarget_24917 crossref_primary_10_1002_ijc_29539 crossref_primary_10_1038_s43018_020_00145_w crossref_primary_10_1007_s12079_019_00508_8 crossref_primary_10_3389_fphar_2021_639256 crossref_primary_10_3390_nu16050708 crossref_primary_10_1016_j_bbcan_2022_188800 crossref_primary_10_1007_s13277_016_5123_x crossref_primary_10_3390_cells14020132 crossref_primary_10_3390_ijms22094490 crossref_primary_10_1002_ijc_28572 crossref_primary_10_1186_s13046_022_02484_1 crossref_primary_10_3389_fmicb_2023_1142283 crossref_primary_10_1016_j_neo_2016_03_003 crossref_primary_10_1016_j_prostaglandins_2014_11_003 crossref_primary_10_1038_s41418_019_0289_6 crossref_primary_10_1186_s12885_022_09330_9 crossref_primary_10_1186_1472_6882_14_153 crossref_primary_10_1016_j_yexcr_2020_111932 crossref_primary_10_18632_oncotarget_15449 crossref_primary_10_1158_1078_0432_CCR_18_3427 crossref_primary_10_1186_s13046_017_0574_5 crossref_primary_10_3390_cancers16040807 crossref_primary_10_1080_20013078_2020_1769373 crossref_primary_10_1016_j_suronc_2017_11_008 crossref_primary_10_1186_s12929_018_0440_6 crossref_primary_10_5761_atcs_cr_13_00202 crossref_primary_10_3390_jcm5070065 crossref_primary_10_3389_fimmu_2021_810286 crossref_primary_10_1016_j_ccell_2014_09_002 crossref_primary_10_1038_s41598_018_27810_6 crossref_primary_10_1016_j_neuint_2021_105081 crossref_primary_10_1038_cdd_2017_70 crossref_primary_10_1002_mog2_70005 crossref_primary_10_3390_foods10061195 crossref_primary_10_1080_01635581_2019_1577979 crossref_primary_10_1158_0008_5472_CAN_17_1686 crossref_primary_10_3390_cells8101143 crossref_primary_10_3390_vetsci10010019 crossref_primary_10_3390_vaccines11010055 crossref_primary_10_3892_ijo_2023_5553 crossref_primary_10_1186_1471_2407_13_317 crossref_primary_10_1158_1078_0432_CCR_15_0780 crossref_primary_10_1002_mc_22335 crossref_primary_10_1016_j_phrs_2016_10_022 crossref_primary_10_18632_oncotarget_23645 crossref_primary_10_3389_fonc_2020_614468 crossref_primary_10_1016_j_jinorgbio_2016_04_014 crossref_primary_10_3389_fonc_2024_1431418 crossref_primary_10_1038_s41388_019_1118_6 crossref_primary_10_3390_cells14020113 crossref_primary_10_1016_j_yexcr_2013_05_031 crossref_primary_10_1038_s41540_024_00422_9 crossref_primary_10_3390_ijms21165744 crossref_primary_10_1186_1756_9966_32_62 crossref_primary_10_1172_JCI121486 crossref_primary_10_1158_1541_7786_MCR_21_0208 crossref_primary_10_1242_jcs_120907 crossref_primary_10_3390_ijms22083935 crossref_primary_10_1016_j_ejso_2015_12_008 crossref_primary_10_1016_j_omtn_2017_03_007 crossref_primary_10_3390_cancers15123152 crossref_primary_10_1016_j_genrep_2023_101848 crossref_primary_10_1021_acs_jafc_1c05585 crossref_primary_10_1016_j_bbcan_2020_188475 crossref_primary_10_1002_jbt_21735 crossref_primary_10_1002_mc_22471 crossref_primary_10_1186_s40478_021_01151_4 crossref_primary_10_1007_s10549_019_05301_0 crossref_primary_10_1016_j_ccell_2016_10_010 crossref_primary_10_3390_cancers6020860 crossref_primary_10_1111_pcmr_12139 crossref_primary_10_3390_jcm8081253 crossref_primary_10_1080_2162402X_2014_1000083 crossref_primary_10_4251_wjgo_v12_i3_301 crossref_primary_10_1007_s12026_013_8434_7 crossref_primary_10_1016_j_cels_2022_10_004 crossref_primary_10_3390_cells10082042 crossref_primary_10_1194_jlr_M084202 crossref_primary_10_18632_oncotarget_11528 crossref_primary_10_3390_cancers15204974 crossref_primary_10_3390_ijms24044002 crossref_primary_10_1038_s41388_019_0848_9 crossref_primary_10_3390_ijms19123890 crossref_primary_10_1016_j_toxicon_2016_01_051 crossref_primary_10_1016_j_trecan_2021_10_006 crossref_primary_10_1021_acsabm_0c00970 crossref_primary_10_1002_dvdy_736 crossref_primary_10_1080_02772248_2015_1137099 crossref_primary_10_3390_cancers13184510 crossref_primary_10_1002_mc_22358 crossref_primary_10_3389_fimmu_2019_01818 crossref_primary_10_1007_s13402_019_00489_1 crossref_primary_10_1111_febs_16021 crossref_primary_10_3389_fphar_2022_1038073 crossref_primary_10_1111_1440_1681_13288 crossref_primary_10_3389_fragi_2022_935220 crossref_primary_10_1002_mc_22240 crossref_primary_10_1007_s10549_013_2737_1 crossref_primary_10_3390_cancers13040687 crossref_primary_10_3892_ijo_2015_3256 crossref_primary_10_1016_j_ejphar_2013_05_046 crossref_primary_10_1016_j_canlet_2014_12_012 crossref_primary_10_1210_endocr_bqaa152 crossref_primary_10_1016_j_stemcr_2017_11_010 crossref_primary_10_1093_sleep_zsac279 crossref_primary_10_3389_fonc_2021_631469 crossref_primary_10_1186_s13020_023_00797_7 crossref_primary_10_1016_j_tranon_2023_101733 crossref_primary_10_3390_ijms19082385 crossref_primary_10_1016_j_chemphyslip_2017_05_012 crossref_primary_10_1016_j_fct_2015_01_012 crossref_primary_10_1165_rcmb_2015_0195OC crossref_primary_10_1158_1078_0432_CCR_16_1955 crossref_primary_10_1016_j_canlet_2015_06_019 crossref_primary_10_1158_1078_0432_CCR_18_3900 crossref_primary_10_1016_j_jss_2012_07_066 crossref_primary_10_3390_cancers6020969 crossref_primary_10_1007_s11010_016_2818_7 crossref_primary_10_1371_journal_pone_0056664 crossref_primary_10_1593_neo_131688 crossref_primary_10_1002_med_21948 crossref_primary_10_1016_j_mce_2013_06_003 crossref_primary_10_3892_ijo_2013_1852 crossref_primary_10_3892_ijo_2015_3245 crossref_primary_10_3389_fonc_2022_910678 crossref_primary_10_3390_biomedicines8110516 crossref_primary_10_3390_cimb45050251 crossref_primary_10_1038_s41392_024_01757_9 crossref_primary_10_1186_s13048_016_0258_3 crossref_primary_10_1016_j_bbrc_2014_11_014 crossref_primary_10_1186_s12903_024_04040_z crossref_primary_10_3390_ijms25168972 crossref_primary_10_1136_jitc_2022_004832 crossref_primary_10_3892_or_2013_2841 crossref_primary_10_1186_s13058_015_0531_1 crossref_primary_10_1007_s13402_017_0341_9 crossref_primary_10_3390_biology11101481 crossref_primary_10_3390_cells7090125 crossref_primary_10_2147_CMAR_S245283 crossref_primary_10_1007_s12272_024_01497_y crossref_primary_10_1016_j_canlet_2020_05_012 crossref_primary_10_1016_j_ccell_2018_01_009 crossref_primary_10_3390_cancers16213572 crossref_primary_10_1158_1078_0432_CCR_13_3173 crossref_primary_10_1158_1535_7163_MCT_17_1261 crossref_primary_10_1002_tox_23785 crossref_primary_10_1038_s41375_019_0674_7 crossref_primary_10_1101_gad_225334_113 crossref_primary_10_3389_fonc_2017_00145 crossref_primary_10_1152_ajplung_00224_2016 crossref_primary_10_1186_s13287_020_02113_8 crossref_primary_10_18632_oncotarget_14608 crossref_primary_10_3390_genes10120961 crossref_primary_10_3390_ijms19030844 crossref_primary_10_1016_j_semcancer_2012_05_004 crossref_primary_10_1158_1535_7163_MCT_12_0304 crossref_primary_10_1007_s11739_023_03281_0 crossref_primary_10_1158_0008_5472_CAN_12_2095 crossref_primary_10_1016_j_arr_2023_102115 crossref_primary_10_1038_srep18208 crossref_primary_10_1186_s12885_020_07228_y crossref_primary_10_1093_carcin_bgt040 crossref_primary_10_3389_fonc_2020_00584 crossref_primary_10_1002_jcb_25219 crossref_primary_10_3389_fonc_2014_00358 crossref_primary_10_1186_s12943_015_0454_6 crossref_primary_10_1038_onc_2016_332 crossref_primary_10_1007_s10585_020_10021_7 crossref_primary_10_1080_19491034_2016_1150392 crossref_primary_10_1016_j_clinsp_2023_100276 crossref_primary_10_3390_ijms24021221 crossref_primary_10_1002_mc_23482 crossref_primary_10_3389_fmicb_2020_01301 crossref_primary_10_1007_s11010_021_04089_2 crossref_primary_10_1371_journal_pone_0069067 crossref_primary_10_1038_s41598_020_69907_x crossref_primary_10_3390_jpm12081284 crossref_primary_10_1016_j_devcel_2024_05_007 crossref_primary_10_3390_nu11030704 crossref_primary_10_1016_j_molonc_2016_01_002 crossref_primary_10_1111_febs_14444 crossref_primary_10_18632_oncotarget_11454 crossref_primary_10_1016_j_adcanc_2022_100055 crossref_primary_10_3892_wasj_2025_330 crossref_primary_10_3390_biomedicines6010036 crossref_primary_10_1183_09031936_00100412 crossref_primary_10_1016_j_gpb_2017_06_002 crossref_primary_10_1007_s13277_015_4450_7 crossref_primary_10_1038_s41467_018_06268_0 crossref_primary_10_1083_jcb_201307066 crossref_primary_10_1002_ijc_30932 crossref_primary_10_1016_j_jcmgh_2023_08_001 crossref_primary_10_18632_oncotarget_3462 crossref_primary_10_1158_0008_5472_CAN_15_2926 crossref_primary_10_3390_cancers13174302 crossref_primary_10_3390_ijms23137437 crossref_primary_10_1007_s12195_021_00694_9 crossref_primary_10_1016_j_yexcr_2016_03_009 crossref_primary_10_1186_s12943_016_0576_5 crossref_primary_10_1038_s41467_018_04313_6 crossref_primary_10_1074_jbc_RA118_003662 crossref_primary_10_1016_j_bcp_2020_114152 crossref_primary_10_1155_2013_962038 crossref_primary_10_3892_or_2012_2191 crossref_primary_10_1038_bonekey_2015_75 crossref_primary_10_1158_1940_6207_CAPR_12_0431 crossref_primary_10_1016_j_oraloncology_2015_07_006 crossref_primary_10_1038_s41598_024_67587_5 crossref_primary_10_12677_tcm_2024_135159 crossref_primary_10_3390_cancers14030539 crossref_primary_10_1186_s12918_017_0393_5 crossref_primary_10_1016_j_plipres_2025_101330 crossref_primary_10_1371_journal_pgen_1005734 crossref_primary_10_3389_fonc_2018_00505 crossref_primary_10_3390_cancers6010211 crossref_primary_10_1038_oncsis_2017_85 crossref_primary_10_18632_oncotarget_2384 crossref_primary_10_1002_jcp_27222 crossref_primary_10_1016_j_cell_2023_02_020 crossref_primary_10_1007_s00262_014_1550_y crossref_primary_10_1007_s12032_012_0305_x crossref_primary_10_1016_j_bcp_2016_06_014 crossref_primary_10_3390_biology11020259 crossref_primary_10_1016_j_biopha_2022_113932 crossref_primary_10_1016_j_molimm_2017_12_011 crossref_primary_10_1002_jcb_27588 crossref_primary_10_1016_j_bbrc_2012_10_097 crossref_primary_10_1016_j_lungcan_2018_12_001 crossref_primary_10_1186_s13020_019_0257_6 crossref_primary_10_1016_j_ejca_2013_10_001 crossref_primary_10_3390_ijms22105086 crossref_primary_10_3892_or_2017_5369 crossref_primary_10_3389_fonc_2020_00554 crossref_primary_10_1038_s41598_020_64298_5 crossref_primary_10_18632_oncotarget_11232 crossref_primary_10_18632_oncotarget_8917 crossref_primary_10_3390_cells13110942 crossref_primary_10_1080_19336918_2017_1322253 crossref_primary_10_1002_cnr2_1291 crossref_primary_10_1016_S2213_2600_13_70159_0 crossref_primary_10_1155_2016_5285892 crossref_primary_10_3389_fonc_2022_911410 crossref_primary_10_1038_s41388_021_01708_6 crossref_primary_10_1093_jnci_djw209 crossref_primary_10_1007_s11010_020_04044_7 crossref_primary_10_1631_jzus_B1300264 crossref_primary_10_3390_ijms22094673 crossref_primary_10_1002_jcp_24832 crossref_primary_10_1007_s00262_021_02862_2 crossref_primary_10_1111_php_12758 crossref_primary_10_4252_wjsc_v5_i4_188 crossref_primary_10_1111_hel_12813 crossref_primary_10_1158_2326_6066_CIR_14_0112 crossref_primary_10_1242_jcs_259018 crossref_primary_10_1016_j_intimp_2013_03_034 crossref_primary_10_3892_or_2016_5024 crossref_primary_10_1007_s10735_021_09971_3 crossref_primary_10_1016_j_jare_2013_06_004 crossref_primary_10_3390_nu13072431 crossref_primary_10_1186_s12864_015_1707_x crossref_primary_10_1016_j_ebiom_2018_12_047 crossref_primary_10_1038_s41598_017_02190_5 crossref_primary_10_3390_cancers10090287 crossref_primary_10_1016_j_cellimm_2015_11_007 crossref_primary_10_1038_onc_2013_39 crossref_primary_10_1080_2162402X_2017_1423170 crossref_primary_10_18632_oncotarget_9111 crossref_primary_10_4161_cc_26388 crossref_primary_10_1038_srep16578 crossref_primary_10_2217_nnm_2018_0379 crossref_primary_10_1016_j_omtn_2018_07_013 crossref_primary_10_1038_onc_2015_291 crossref_primary_10_1530_ERC_15_0218 |
Cites_doi | 10.1172/JCI26322 10.1016/j.cell.2008.03.027 10.1016/S1535-6108(02)00154-X 10.1016/j.ccr.2009.03.016 10.1038/nri1703 10.1146/annurev.immunol.021908.132641 10.1136/jcp.2006.039099 10.1158/1078-0432.CCR-08-0123 10.1074/jbc.M707429200 10.1084/jem.193.4.417 10.1016/S0092-8674(04)00302-2 10.1186/1471-2407-9-240 10.1074/jbc.274.43.30353 10.1128/MCB.01219-06 10.1038/sj.bjc.6605530 10.1038/nrc822 10.1016/j.molcel.2007.02.019 10.1158/0008-5472.CAN-07-0575 10.1038/sj.cdd.4401744 10.1016/j.cell.2009.11.007 10.1158/0008-5472.CAN-04-3785 10.1016/j.cell.2004.06.006 10.1593/neo.04352 10.1016/j.humpath.2005.12.021 10.1083/jcb.200109037 10.1038/sj.onc.1209808 10.1016/j.ccr.2010.10.035 10.1593/neo.91084 10.1038/nrc2131 10.1016/S0092-8674(03)00002-3 10.1016/j.ceb.2005.08.001 10.1172/JCI200421358 10.1016/j.cell.2007.05.058 |
ContentType | Journal Article |
Copyright | 2015 INIST-CNRS |
Copyright_xml | – notice: 2015 INIST-CNRS |
DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7TO H94 7X8 |
DOI | 10.1158/0008-5472.CAN-11-3123 |
DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Oncogenes and Growth Factors Abstracts AIDS and Cancer Research Abstracts MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Oncogenes and Growth Factors Abstracts AIDS and Cancer Research Abstracts MEDLINE - Academic |
DatabaseTitleList | Oncogenes and Growth Factors Abstracts MEDLINE MEDLINE - Academic CrossRef |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1538-7445 |
EndPage | 1300 |
ExternalDocumentID | 22253230 25863056 10_1158_0008_5472_CAN_11_3123 |
Genre | Research Support, U.S. Gov't, Non-P.H.S Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
GrantInformation_xml | – fundername: NCI NIH HHS grantid: CA16672 – fundername: NCI NIH HHS grantid: P30 CA016672 – fundername: NCI NIH HHS grantid: P50 CA116199 – fundername: NCI NIH HHS grantid: R01 CA109311 – fundername: NCI NIH HHS grantid: CA109311 – fundername: NCI NIH HHS grantid: CA09903 – fundername: NCI NIH HHS grantid: P01 CA099031 |
GroupedDBID | --- -ET 18M 29B 2WC 34G 39C 3O- 53G 5GY 5RE 5VS 6J9 AAFWJ AAJMC AAYXX ABOCM ACGFO ACIWK ACPRK ACSVP ADBBV ADCOW AENEX AETEA AFHIN AFOSN AFRAH AFUMD ALMA_UNASSIGNED_HOLDINGS BAWUL BTFSW CITATION CS3 DIK DU5 EBS EJD F5P FRP GX1 H13 IH2 KQ8 L7B LSO OK1 P0W P2P PQQKQ RCR RHI RNS SJN TR2 UDS W2D W8F WH7 WOQ YKV YZZ .55 .GJ 8WZ A6W ADNWM AFFNX AI. C1A D0S IQODW J5H MVM OHT VH1 WHG X7M XJT ZCG ZGI CGR CUY CVF ECM EIF NPM 7TO H94 7X8 |
ID | FETCH-LOGICAL-c418t-82469c5dd740e902625ebeaac7e5d68598b2ef362e37826fb87e1a0495f3a79d3 |
ISSN | 0008-5472 1538-7445 |
IngestDate | Fri Jul 11 08:18:05 EDT 2025 Tue Aug 05 10:22:07 EDT 2025 Mon Jul 21 06:06:19 EDT 2025 Mon Jul 21 09:14:20 EDT 2025 Tue Jul 01 02:08:17 EDT 2025 Thu Apr 24 23:08:22 EDT 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Keywords | Transcription factor NFκB Epithelial mesenchymal transition Transcription Cell transformation Tumor necrosis factor α Cytokine |
Language | English |
License | CC BY 4.0 |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c418t-82469c5dd740e902625ebeaac7e5d68598b2ef362e37826fb87e1a0495f3a79d3 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Article-1 ObjectType-Feature-2 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/3350107 |
PMID | 22253230 |
PQID | 1008833444 |
PQPubID | 23462 |
PageCount | 11 |
ParticipantIDs | proquest_miscellaneous_993104934 proquest_miscellaneous_1008833444 pubmed_primary_22253230 pascalfrancis_primary_25863056 crossref_primary_10_1158_0008_5472_CAN_11_3123 crossref_citationtrail_10_1158_0008_5472_CAN_11_3123 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2012-03-01 |
PublicationDateYYYYMMDD | 2012-03-01 |
PublicationDate_xml | – month: 03 year: 2012 text: 2012-03-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | Philadelphia, PA |
PublicationPlace_xml | – name: Philadelphia, PA – name: United States |
PublicationTitle | Cancer research (Chicago, Ill.) |
PublicationTitleAlternate | Cancer Res |
PublicationYear | 2012 |
Publisher | American Association for Cancer Research |
Publisher_xml | – name: American Association for Cancer Research |
References | Vesuna (2022061703493681200_bib28) 2009; 11 Karin (2022061703493681200_bib1) 2005; 5 Hu (2022061703493681200_bib23) 2004; 117 Yuen (2022061703493681200_bib10) 2007; 60 Huang (2022061703493681200_bib21) 2007; 26 Lee (2022061703493681200_bib13) 2008; 14 Cheng (2022061703493681200_bib32) 2008; 283 Huber (2022061703493681200_bib16) 2004; 114 Elias (2022061703493681200_bib12) 2005; 7 Thiery (2022061703493681200_bib31) 2009; 139 Wu (2022061703493681200_bib14) 2010; 102 Matsuo (2022061703493681200_bib11) 2009; 9 Vallabhapurapu (2022061703493681200_bib15) 2009; 27 Wu (2022061703493681200_bib18) 2009; 15 Kwok (2022061703493681200_bib8) 2005; 65 Thiery (2022061703493681200_bib4) 2002; 2 Kyo (2022061703493681200_bib9) 2006; 37 Luo (2022061703493681200_bib2) 2005; 115 Lo (2022061703493681200_bib24) 2007; 67 Sosic (2022061703493681200_bib33) 2003; 112 Janda (2022061703493681200_bib27) 2002; 156 Peinado (2022061703493681200_bib6) 2007; 7 Demontis (2022061703493681200_bib26) 2006; 13 Howe (2022061703493681200_bib34) 2003; 63 Chua (2022061703493681200_bib17) 2007; 26 Huber (2022061703493681200_bib5) 2005; 17 Kaisho (2022061703493681200_bib3) 2001; 193 Yang (2022061703493681200_bib7) 2004; 117 Deng (2022061703493681200_bib22) 2002; 2 Pham (2022061703493681200_bib19) 2007; 27 Sakurai (2022061703493681200_bib29) 1999; 274 Lee (2022061703493681200_bib20) 2007; 130 Chang (2022061703493681200_bib25) 2011; 19 Mani (2022061703493681200_bib30) 2008; 133 |
References_xml | – volume: 115 start-page: 2625 year: 2005 ident: 2022061703493681200_bib2 article-title: IKK/NF-kappaB signaling: balancing life and death–a new approach to cancer therapy publication-title: J Clin Invest doi: 10.1172/JCI26322 – volume: 133 start-page: 704 year: 2008 ident: 2022061703493681200_bib30 article-title: The epithelial-mesenchymal transition generates cells with properties of stem cells publication-title: Cell doi: 10.1016/j.cell.2008.03.027 – volume: 2 start-page: 323 year: 2002 ident: 2022061703493681200_bib22 article-title: beta-catenin interacts with and inhibits NF-kappa B in human colon and breast cancer publication-title: Cancer Cell doi: 10.1016/S1535-6108(02)00154-X – volume: 15 start-page: 416 year: 2009 ident: 2022061703493681200_bib18 article-title: Stabilization of snail by NF-kappaB is required for inflammation-induced cell migration and invasion publication-title: Cancer Cell doi: 10.1016/j.ccr.2009.03.016 – volume: 63 start-page: 1906 year: 2003 ident: 2022061703493681200_bib34 article-title: Twist is up-regulated in response to Wnt1 and inhibits mouse mammary cell differentiation publication-title: Cancer Res – volume: 5 start-page: 749 year: 2005 ident: 2022061703493681200_bib1 article-title: NF-kappaB: linking inflammation and immunity to cancer development and progression publication-title: Nat Rev Immunol doi: 10.1038/nri1703 – volume: 27 start-page: 693 year: 2009 ident: 2022061703493681200_bib15 article-title: Regulation and function of NF-kappaB transcription factors in the immune system publication-title: Annu Rev Immunol doi: 10.1146/annurev.immunol.021908.132641 – volume: 60 start-page: 510 year: 2007 ident: 2022061703493681200_bib10 article-title: Upregulation of Twist in oesophageal squamous cell carcinoma is associated with neoplastic transformation and distant metastasis publication-title: J Clin Pathol doi: 10.1136/jcp.2006.039099 – volume: 14 start-page: 5656 year: 2008 ident: 2022061703493681200_bib13 article-title: Advances in targeting IKK and IKK-related kinases for cancer therapy publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-08-0123 – volume: 283 start-page: 14665 year: 2008 ident: 2022061703493681200_bib32 article-title: Twist is transcriptionally induced by activation of STAT3 and mediates STAT3 oncogenic function publication-title: J Biol Chem doi: 10.1074/jbc.M707429200 – volume: 193 start-page: 417 year: 2001 ident: 2022061703493681200_bib3 article-title: IkappaB kinase alpha is essential for mature B cell development and function publication-title: J Exp Med doi: 10.1084/jem.193.4.417 – volume: 117 start-page: 225 year: 2004 ident: 2022061703493681200_bib23 article-title: IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a publication-title: Cell doi: 10.1016/S0092-8674(04)00302-2 – volume: 9 start-page: 240 year: 2009 ident: 2022061703493681200_bib11 article-title: Twist expression promotes migration and invasion in hepatocellular carcinoma publication-title: BMC Cancer doi: 10.1186/1471-2407-9-240 – volume: 274 start-page: 30353 year: 1999 ident: 2022061703493681200_bib29 article-title: IkappaB kinases phosphorylate NF-kappaB p65 subunit on serine 536 in the transactivation domain publication-title: J Biol Chem doi: 10.1074/jbc.274.43.30353 – volume: 27 start-page: 3920 year: 2007 ident: 2022061703493681200_bib19 article-title: Upregulation of Twist-1 by NF-kappaB blocks cytotoxicity induced by chemotherapeutic drugs publication-title: Mol Cell Biol doi: 10.1128/MCB.01219-06 – volume: 102 start-page: 639 year: 2010 ident: 2022061703493681200_bib14 article-title: TNF-alpha/NF-kappaB/Snail pathway in cancer cell migration and invasion publication-title: Br J Cancer doi: 10.1038/sj.bjc.6605530 – volume: 2 start-page: 442 year: 2002 ident: 2022061703493681200_bib4 article-title: Epithelial-mesenchymal transitions in tumour progression publication-title: Nat Rev Cancer doi: 10.1038/nrc822 – volume: 26 start-page: 75 year: 2007 ident: 2022061703493681200_bib21 article-title: Phosphorylation of CBP by IKKalpha promotes cell growth by switching the binding preference of CBP from p53 to NF-kappaB publication-title: Mol Cell doi: 10.1016/j.molcel.2007.02.019 – volume: 67 start-page: 9066 year: 2007 ident: 2022061703493681200_bib24 article-title: Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-07-0575 – volume: 13 start-page: 335 year: 2006 ident: 2022061703493681200_bib26 article-title: Twist is substrate for caspase cleavage and proteasome-mediated degradation publication-title: Cell Death Differ doi: 10.1038/sj.cdd.4401744 – volume: 139 start-page: 871 year: 2009 ident: 2022061703493681200_bib31 article-title: Epithelial-mesenchymal transitions in development and disease publication-title: Cell doi: 10.1016/j.cell.2009.11.007 – volume: 65 start-page: 5153 year: 2005 ident: 2022061703493681200_bib8 article-title: Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-04-3785 – volume: 117 start-page: 927 year: 2004 ident: 2022061703493681200_bib7 article-title: Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis publication-title: Cell doi: 10.1016/j.cell.2004.06.006 – volume: 7 start-page: 824 year: 2005 ident: 2022061703493681200_bib12 article-title: TWIST is expressed in human gliomas and promotes invasion publication-title: Neoplasia doi: 10.1593/neo.04352 – volume: 37 start-page: 431 year: 2006 ident: 2022061703493681200_bib9 article-title: High Twist expression is involved in infiltrative endometrial cancer and affects patient survival publication-title: Hum Pathol doi: 10.1016/j.humpath.2005.12.021 – volume: 156 start-page: 299 year: 2002 ident: 2022061703493681200_bib27 article-title: Ras and TGF[beta] cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways publication-title: J Cell Biol doi: 10.1083/jcb.200109037 – volume: 26 start-page: 711 year: 2007 ident: 2022061703493681200_bib17 article-title: NF-kappaB represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: potential involvement of ZEB-1 and ZEB-2 publication-title: Oncogene doi: 10.1038/sj.onc.1209808 – volume: 19 start-page: 86 year: 2011 ident: 2022061703493681200_bib25 article-title: EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-beta-catenin signaling publication-title: Cancer Cell doi: 10.1016/j.ccr.2010.10.035 – volume: 11 start-page: 1318 year: 2009 ident: 2022061703493681200_bib28 article-title: Twist modulates breast cancer stem cells by transcriptional regulation of CD24 expression publication-title: Neoplasia doi: 10.1593/neo.91084 – volume: 7 start-page: 415 year: 2007 ident: 2022061703493681200_bib6 article-title: Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? publication-title: Nat Rev Cancer doi: 10.1038/nrc2131 – volume: 112 start-page: 169 year: 2003 ident: 2022061703493681200_bib33 article-title: Twist regulates cytokine gene expression through a negative feedback loop that represses NF-kappaB activity publication-title: Cell doi: 10.1016/S0092-8674(03)00002-3 – volume: 17 start-page: 548 year: 2005 ident: 2022061703493681200_bib5 article-title: Molecular requirements for epithelial-mesenchymal transition during tumor progression publication-title: Curr Opin Cell Biol doi: 10.1016/j.ceb.2005.08.001 – volume: 114 start-page: 569 year: 2004 ident: 2022061703493681200_bib16 article-title: NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression publication-title: J Clin Invest doi: 10.1172/JCI200421358 – volume: 130 start-page: 440 year: 2007 ident: 2022061703493681200_bib20 article-title: IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway publication-title: Cell doi: 10.1016/j.cell.2007.05.058 |
SSID | ssj0005105 |
Score | 2.550296 |
Snippet | Proinflammatory cytokines produced in the tumor microenvironment facilitate tumor development and metastatic progression. In particular, TNF-α promotes cancer... Proinflammatory cytokines produced in the tumor microenvironment facilitate tumor development and metastatic progression. In particular, TNF- alpha promotes... |
SourceID | proquest pubmed pascalfrancis crossref |
SourceType | Aggregation Database Index Database Enrichment Source |
StartPage | 1290 |
SubjectTerms | Animals Antineoplastic agents Biological and medical sciences Breast Neoplasms - genetics Breast Neoplasms - pathology Carrier Proteins - metabolism Cell Line, Tumor Epithelial-Mesenchymal Transition Female Humans I-kappa B Kinase - physiology Inflammation - genetics Intracellular Signaling Peptides and Proteins Lung Neoplasms - secondary Mammary Neoplasms, Experimental - pathology Medical sciences Mice Mice, Inbred BALB C Neoplasm Proteins - metabolism NF-kappa B - metabolism Nuclear Proteins - genetics Pharmacology. Drug treatments Transcriptional Activation Transfection Tumor Necrosis Factor-alpha - genetics Tumor Necrosis Factor-alpha - pharmacology Tumors Twist-Related Protein 1 - genetics Up-Regulation |
Title | Epithelial–Mesenchymal Transition Induced by TNF-α Requires NF-κB–Mediated Transcriptional Upregulation of Twist1 |
URI | https://www.ncbi.nlm.nih.gov/pubmed/22253230 https://www.proquest.com/docview/1008833444 https://www.proquest.com/docview/993104934 |
Volume | 72 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swEBdZB2Mwxr6Xbisa7C0oS2zLlh-7kFDWJGXMYXkzsi21gSwxaULJ2MP-9N1JduyMlHV7MeHQh-P76XQn3QchH4Svw46G9a0BTsxzspAliUhYIv3QV4FKgwRvdEdj_2zifZ7yaaPxq-a1tFkn7fTHwbiS_-Eq0ICvGCX7D5zdDQoE-A38hSdwGJ534nE_x4iKOUzERhhFlF5tv2O8Pe4_xhWrhZU5UqtkRuMBa5nQWvim6P-rQMQB6VzmuWx9YiNTtAPamu6lMIHhJvnKFqwvdMvoBqDRrWu1PYTOqlUkDroyN8PWxcOIoPm8XTtwGM7sNf9Msm9qVlKn1mkXKFtZQc30Hy4Xl7pqObT1n78qEFPsQtWPLdD_o_Tb2oliwbgX7IniwKlBjtfkKp6W1fZovIM7LP-5sA6Tdux273Rs8jR2bVDzfr7t8UU8mAyHcdSfRvfIfQcMDZSU51-qfPO8cIItByxiwGCajwcn2dNuHuXyGhaathVSbjdhjCoTPSGPCxuEnlpAPSUNtXhGHowKL4vn5OdhXNEKV7TAFU22FHFFDa5oiSuKJIMrWuGK_oErWscVXWpqcfWCTAb9qHfGiiodLPW6Ys2E4_lhyrMs8DoqBJPe4SAYpEwDxTNf8FAkjtKgJykXtFFfJyJQXQmGKdeuDMLMfUmOFsuFek2o44QqAwM-kKDkuk4nFCKBLShItRBSc69JvPLrxmmRwh4rqcxjY8pyga4UIkamxMAUIMXIlCZp77rlNofL3zqc7LFu18vhwkebu0nel7yMQRzjHZtcqOXmGlOAY_luz4OXpbe0AZOgC__fhSavLA6qCWB7dR23c3yHCd6Qh9XCekuO1quNegca8jo5MSD-DU4mtag |
linkProvider | Colorado Alliance of Research Libraries |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Epithelial-Mesenchymal+Transition+Induced+by+TNF-+alpha+Requires+NF-+Kappa+B-Mediated+Transcriptional+Upregulation+of+Twist1&rft.jtitle=Cancer+research+%28Chicago%2C+Ill.%29&rft.au=Li%2C+Chia-Wei&rft.au=Xia%2C+Weiya&rft.au=Huo%2C+Longfei&rft.au=Lim%2C+Seung-Oe&rft.date=2012-03-01&rft.issn=0008-5472&rft.volume=72&rft.issue=5&rft.spage=1290&rft.epage=1300&rft_id=info:doi/10.1158%2F0008-5472.CAN-11-3123&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0008-5472&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0008-5472&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0008-5472&client=summon |